Target
DNMT1
1 product, 1 indication
Indications
Melanoma and Merkel Cell Carcinoma (1 products)
Loading...
1 drug
10 abstracts
Abstract
A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Org: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Centre Hospitalier Régional Universitaire de Nîmes, Hopital Cochin, Groupement des Hôpitaux de l'Institut Catholique de Lille,
Abstract
A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.Org: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hygeia Suzhou Yongding Hospital, National Regional Medical Center,
Abstract
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).Org: Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Division of Hematology Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, Division of Medical Oncology, Mayo Clinic,
Abstract
Outcomes of 10-day decitabine with venetoclax for AML.Org: Medical University of South Carolina Hollings Cancer Center,
Abstract
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).Org: Novartis Pharma AG, Novartis Oncology, Genesis Research, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine,
Abstract
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Homologous recombination deficiency (HRD) status to predict the efficacy and prognosis of platinum-based neoadjuvant chemotherapy in patients with triple-negative breast cancer.Org: Fujian Medical University Union Hospital, Amoy Diagnostics Co., Ltd.,
Abstract
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.Org: Virginia Commonwealth University School of Medicine, VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,
Abstract
Transformation of tissue-resident, very small embryonic-like stem cells (VSELs) into cancer stem cells (CSCs) and its role in cancer initiation via epigenetic changes.Org: Epigeneres Biotech Pvt. Ltd., National Institute for Research in Reproductive and Child Health,
Drug
Decitabine